A new blood test could mark an important step in the early diagnosis of Alzheimer’s disease, as it promises to identify pathological changes in the brain up to a decade before the first symptoms appear.

The development was presented at the Alzheimer’s Association International Conference, where researchers presented the results of a test based on the blood biomarker p-tau217.

AD PLACEHOLDER

The test measures the level of the p-tau217 protein, which is considered a highly reliable indicator of the buildup of amyloid plaques in the brain – one of the main biological hallmarks of Alzheimer’s disease.

According to the researchers, high levels of this protein can accurately predict the formation of amyloid plaques even in people who do not yet show symptoms such as memory loss, confusion or difficulty thinking, Dukagjini reports.

Delores Hurst, executive director of the Arkansas chapter of the Alzheimer’s Association, said the test significantly improves diagnostic accuracy. According to her, neurologists achieve an accuracy rate of around 76%, while primary care physicians achieve around 65%, but the new test eliminates this gap by enabling family doctors to reliably identify patients at risk as well.

Experts estimate that using this test could reduce the need for costly examinations such as PET scans and speed up early diagnosis, creating opportunities for quicker intervention and more effective treatment.